Background Recurrent head and neck squamous cell carcinoma (rHNSCC) represents a
significant global health burden with an unmet medical need. In this study we determined …

Background To determine the safety, preliminary efficacy, pharmacokinetics, and
immunogenicity of a single cycle of RM-1929 photoimmunotherapy, an anti-EGFR antibody …

Near-infrared photoimmunotherapy (NIR-PIT) is a recently developed hybrid cancer therapy
that directly kills cancer cells as well as producing a therapeutic host immune response …

ABSTRACT In September 2020, the Japanese government approved cetuximab saratolacan
(previously known as RM-1929, commercial name: Akalux) for the treatment of unresectable …

PURPOSE To provide evidence-based recommendations for practicing physicians and
other health care providers on immunotherapy and biomarker testing for head and neck …

Purpose Treatment options for patients with platinum-refractory recurrent or metastatic
squamous cell carcinoma of the head and neck (R/M SCCHN) are limited. The purpose of …

Introduction: The majority of patients with locally advanced head and neck squamous cell
carcinoma (HNSCC) will recur. The treatment of patients with recurrent/metastatic (R/M …

Near-infrared photoimmunotherapy (NIR-PIT) is a newly-developed, highly-selective cancer
treatment, which utilizes a monoclonal antibody conjugated to a photoabsorbing dye …

Background: KEYNOTE-048 was an open-label, randomized phase 3 study of P or P+
chemotherapy (C) vs EXTREME (E) as first-line systemic therapy for R/M HNSCC …

Importance Immunotherapy for recurrent and/or metastatic (R/M) squamous cell carcinoma
of the head and neck (SCCHN) is promising. The toll-like receptor 8 (TLR8) agonist …